Quality and Regulatory Sourcebook eBook
Read the article:
Assessing the Quality of CAR-T Cells Using ddPCR
Read the eBook:
BioPharm International’s Quality and Regulatory Sourcebook eBook
CAR-T cell therapy development is a complex process that requires standardization.
tilialucida/Stock.adobe.com
With the growth of chimeric antigen receptor (CAR)-T cell therapies comes the realization across the industry that CAR-T cell therapy development is a complex process requiring standardization, regulation, and meticulous quality control to generate safe and effective therapies. In addition, when developing CAR-T cells, biomanufacturers can have their choice of cell sources and bioprocesses, which can lead to variability in success as well as openings for inefficiency and waste. Analytical tools such as droplet digital polymerase chain reaction (ddPCR), a technology platform used to quantify nucleic acids, can support CAR-T cell manufacturers in developing successful CAR-T cell products.
Read the article:
Assessing the Quality of CAR-T Cells Using ddPCR
Read the eBook:
BioPharm International’s Quality and Regulatory Sourcebook eBook
Read this article in BioPharm International’s March 2022 Quality and Regulatory Sourcebook eBook.
Mark White, PhD, is the associate director of Biopharma Product Marketing, and Marwan Alsarraj is the Biopharma Segment manager; both are at Bio-Rad.
BioPharm International
eBook: Quality and Regulatory Sourcebook, March 2022
March 2022
Pages: 4–7
When referring to this article, please cite it as M. White and M. Alsarraj, “Assessing the Quality of CAR-T Cells Using ddPCR," BioPharm International Quality and Regulatory Sourcebook eBook (March 2022).
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.